TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2673479

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Relatives group (compliant families)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Relatives group (non-compliant families)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Family therapy and relatives group (general outcome)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Reduction in EE and/or contact
Number of subjects: 23
Study: 30012798

Group type: EXPERIMENTAL
Intervention: Regular telephone calls and home visits by healthcare professionals after discharge from hospital.
Number of subjects: 0
Study: 27630497

Group type: EXPERIMENTAL
Intervention: Bioactive Glass (BAG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 22
Study: 25432324

Group type: EXPERIMENTAL
Intervention: PEEK interbody cages containing calcium sulphate/demineralized bone matrix (CS/DBM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Autogenous iliac cancellous bone (AIB)
Number of subjects: 68
Study: 23668931

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 100 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg b.i.d. plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg b.i.d. plus reduced tacrolimus (rTAC; 2‐5 ng/mL)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Enteric-coated mycophenolic acid (MPA) plus standard tacrolimus (sTAC; 5‐12 ng/mL)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg and 300 mg
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sotrastaurin groups
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sotrastaurin (all doses)
Number of subjects: 298
Study: 20386125

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 43% 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 23% 1RM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study: 18436117

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day (prava40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (atorva10)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (atorva80)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16950753

Group type: EXPERIMENTAL
Intervention: Hypo-caloric diet for obese women
Number of subjects: 36
Study: 12759881

Group type: EXPERIMENTAL
Intervention: Troglitazone (TGZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 0
Study: 11043625

Group type: EXPERIMENTAL
Intervention: Maternal creatine phosphokinase (CPK) levels >70 mIU/dL
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CPK >70 mIU/dL
Number of subjects: 42
Study: 9168185

Group type: EXPERIMENTAL
Intervention: Telephone counseling (with booster)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Telephone confirmation
Number of subjects: 828

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Telephone counseling (prior to initial visit)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Telephone confirmation (for 6-month follow-up)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Standard care (for 6-month follow-up)
Number of subjects: 828
Study: 8477190

Group type: EXPERIMENTAL
Intervention: IFN alpha alone (arm A)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: IFN alpha and IFN gamma (arm B)
Number of subjects: 131
Study: 3797397

Group type: EXPERIMENTAL
Intervention: Community-wide screening and education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excluded from the screening and education program
Number of subjects: 0
Study: 30048834

Group type: EXPERIMENTAL
Intervention: 3-week inpatient pulmonary rehabilitation
Number of subjects: 590
Study: 27423981

Group type: EXPERIMENTAL
Intervention: Invasive strategy (routine coronary angiogram, n=52)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conservative strategy (coronary angiogram only if recurrent ischemia or heart failure, n=54)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 106
Study: 24507016

Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine) 1-4 mg twice daily (BID)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine) 1-4 mg BID
Number of subjects: 614
Study: 22753445

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 20400408

Group type: EXPERIMENTAL
Intervention: etravirine
Number of subjects: 1203

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study: 18722869

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 883

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 883

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 883
Study: 16908768

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare metal BxVelocity stents
Number of subjects: 200
Study: 14626182

Group type: EXPERIMENTAL
Intervention: Composite Zaizhang decoction (ZZD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 0
Study: 10857523

Group type: EXPERIMENTAL
Intervention: Moderate exercise using arm and bicycle ergometers performed twice a day, 5 times a week, for 14 days, at 60% of maximal heart rate.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 35
Study: 9190630

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 2646
Study: 8254142

Group type: EXPERIMENTAL
Intervention: Light treatment administered at the first signs of winter depression
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 27
Study: 3799250

Group type: EXPERIMENTAL
Intervention: Transnasal operation of the pituitary adenoma
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 31276886

Group type: EXPERIMENTAL
Intervention: Glyphosate (1 mg/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roundup (1 mg/L of glyphosate a.e.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glyphosate or Roundup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roundup (1 mg/L of glyphosate a.e.) with androgenic gland
Number of subjects: 0
Study: 27738796

Group type: COMPARATOR
Intervention: Ondansetron 32-mg infusion over 24 hours
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Olanzapine wafer 10 mg once daily plus ondansetron 8 mg IV three times a day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV
Number of subjects: 62
Study: 25894123

Group type: EXPERIMENTAL
Intervention: Sirolimus + cyclosporine + prednisolone for 3 months followed by sirolimus + prednisolone + mycophenolate mofetil with steroid minimization
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cyclosporine + mycophenolate mofetil + prednisolone
Number of subjects: 113
Study: 23136856

Group type: EXPERIMENTAL
Intervention: Oral miltefosine (100 mg/day for 12 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral miltefosine (100 mg/day for 8 weeks)
Number of subjects: 36
Study: 21513180

Group type: EXPERIMENTAL
Intervention: High salience and high relevance changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-salience changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in the left visual hemifield
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender comparison (men vs. women)
Number of subjects: 0
Study: 19566934

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC)
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112
Study: 17006787

Group type: EXPERIMENTAL
Intervention: 12-month training program
Number of subjects: 19

Group type: COMPARATOR
Intervention: No training group
Number of subjects: 19
Study: 14683522

Group type: EXPERIMENTAL
Intervention: Mediterranean‐inspired diet rich in omega‐3 fatty acids and sterol esters, low in saturated fat, for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ordinary Swedish diet for 4 weeks
Number of subjects: 22
Study: 11331113

Group type: EXPERIMENTAL
Intervention: First aid and home safety training
Number of subjects: 660

Group type: COMPARATOR
Intervention: Tobacco and alcohol prevention
Number of subjects: 660
Study: 9422899

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.0 mg kg-1 i.v.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ketoprofen 0.5 mg kg-1 i.v.
Number of subjects: 107
Study: 8290458

Group type: EXPERIMENTAL
Intervention: OAD cream
Number of subjects: 56
Study: 3014110

Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fed regimen (following a standardized breakfast)
Number of subjects: 18
Study: 30403938

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide and dexamethasone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone alone (control group)
Number of subjects: 117
Study: 26788865

Group type: EXPERIMENTAL
Intervention: APTW imaging for true progression (n=20)
Number of subjects: 32

Group type: COMPARATOR
Intervention: APTW imaging for pseudoprogression (n=12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cutoff APTWmean intensity
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cutoff APTWmax intensity
Number of subjects: 32
Study: 24807604

Group type: EXPERIMENTAL
Intervention: CO2-releasing suppository
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 122
Study: 22233558

Group type: EXPERIMENTAL
Intervention: SRP+LLLT (10 sessions, 830 nm, 100 mW, 3 J per point, 3 J/cm²)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 16
Study: 20444751

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate (MTX) and ciclosporin (CSA), n=80
Number of subjects: 139

Group type: COMPARATOR
Intervention: Initial monotherapy with methotrexate (MTX), n=80
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both treatment groups (MTX + CSA and MTX)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: MRI-bone marrow oedema, TSS, and anti-CCP
Number of subjects: 139
Study: 18635500

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine and 100 mg tramadol (group BT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 100 mg tramadol (group T)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (group B)
Number of subjects: 90
Study: 15837944

Group type: EXPERIMENTAL
Intervention: Diet plus exercise training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (lean children)
Number of subjects: 39
Study: 12392384

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg administered once daily
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 10516539

Group type: EXPERIMENTAL
Intervention: Histamine bronchial challenge
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methacholine bronchial challenge
Number of subjects: 40
Study: 8611112

Group type: EXPERIMENTAL
Intervention: Active loperamide suppositories (20 mg b.d. x 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2167791

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of atrial natriuretic factor at doses of 0.5, 2 and 10 pmol min‐1 kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of atrial natriuretic factor at a pharmacological dose of 50 pmol min‐1 kg‐1
Number of subjects: 8
Study: 6944146

Group type: EXPERIMENTAL
Intervention: Viral oncolysate (formalin-treated fowl plaque virus-infected allogenous leukemia cells) in addition to maintenance chemotherapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 107
Study: 30889042

Group type: EXPERIMENTAL
Intervention: Gemcitabine with bevacizumab
Number of subjects: 294

Group type: COMPARATOR
Intervention: Gemcitabine without bevacizumab
Number of subjects: 294
Study: 29537374

Group type: EXPERIMENTAL
Intervention: BioNIR stent
Number of subjects: 302

Group type: COMPARATOR
Intervention: Resolute Integrity stent
Number of subjects: 302
Study: 26092029

Group type: COMPARATOR
Intervention: Mesh fixation (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No mesh fixation (NO FIX group)
Number of subjects: 60
Study: 24915778

Group type: EXPERIMENTAL
Intervention: Trametinib plus gemcitabine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 160
Study: 21593672

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 116

Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: i-gel (novices)
Number of subjects: 116

Group type: COMPARATOR
Intervention: cLMA (novices)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: i-gel (experienced)
Number of subjects: 116

Group type: COMPARATOR
Intervention: cLMA (experienced)
Number of subjects: 116
Study: 19303238

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral access (USIV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: External jugular vein access (EJ)
Number of subjects: 60
Study: 17683540

Group type: EXPERIMENTAL
Intervention: Coxibs (cyclooxygenase-2 selective inhibitors)
Number of subjects: 49006

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 49006

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 49006

Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 49006

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 49006

Group type: EXPERIMENTAL
Intervention: Coxibs
Number of subjects: 49006
Study: 15249439

Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 24
Study: 11832872

Group type: EXPERIMENTAL
Intervention: High CHO/low fat diet (HC/LF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate CHO and fat diet (MC/MF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Active control group (aerobically trained)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 18
Study: 10410789

Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine 0.1% ophthalmic solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 7538556

Group type: EXPERIMENTAL
Intervention: Peripheral-blood progenitor cells (PBPC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 47
Study: 2405316

Group type: EXPERIMENTAL
Intervention: Cefazolin IV
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cefazolin lavage
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cefamandole IV
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cefamandole lavage
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Endometritis (developed)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Endometritis (not developed)
Number of subjects: 207
Study: 548976

Group type: EXPERIMENTAL
Intervention: Active haemodialysis (AD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham dialysis (SD)
Number of subjects: 12
Study: 31860383

Group type: EXPERIMENTAL
Intervention: Refrigerated formulation (RF) of VGX-3100
Number of subjects: 235

Group type: COMPARATOR
Intervention: Frozen formulation (FF) of VGX-3100
Number of subjects: 235
Study: 30967124

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Landmark method
Number of subjects: 0
Study: 28278558

Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Index (VAI)
Number of subjects: 5312

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 5312
Study: 26134388

Group type: EXPERIMENTAL
Intervention: Flaxseed mucilage (10 g)
Number of subjects: 58

Group type: COMPARATOR
Intervention: L. paracasei F19 (9.4 × 10^10 colony-forming units)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24164570

Group type: EXPERIMENTAL
Intervention: Membrane-covered antrostomy defects
Number of subjects: 109

Group type: COMPARATOR
Intervention: Uncovered antrostomy defects
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Membrane coverage (split-mouth study)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Uncovered (split-mouth study)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Delayed implant placement
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Thick Schneider's membrane (≥2 mm)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Non-smoking
Number of subjects: 109
Study: 21324384

Group type: EXPERIMENTAL
Intervention: Bupivicaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 88

Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 88
Study: 20031746

Group type: EXPERIMENTAL
Intervention: Thrombus-aspiration PCI
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 111
Study: 17890965

Group type: EXPERIMENTAL
Intervention: Cuff inflation at the arm (maximal pressures of 180 and 240 mmHg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cuff inflation at the wrist (maximal pressures of 180 and 240 mmHg)
Number of subjects: 68
Study: 14624322

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 33
Study: 15039810

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 10626860

Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 7547041

Group type: EXPERIMENTAL
Intervention: Lower limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upper limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upper limb IVRA after tourniquet deflation; first 3 min post-deflation.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower limb IVRA after tourniquet deflation; first 3 min post-deflation.
Number of subjects: 10
Study: 1936585

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2 micrograms.kg‐1.min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 6122738

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 200mg twice daily for six weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 100mg at night for one year as maintenance treatment
Number of subjects: 48
Study: 30777772

Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nondrinking control feedback
Number of subjects: 147
Study: 28475678

Group type: EXPERIMENTAL
Intervention: Creatine (20 g/day load×5 days followed by 2 g/day orally)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo (identical to creatine)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 25524863

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum TENSIA in cheese (1×10^10 cfu)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum TENSIA in yoghurt (6×10^9 cfu)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 23404220

Group type: EXPERIMENTAL
Intervention: Barrier® EasyWarm® warming blanket
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard hospital duvet (control)
Number of subjects: 80
Study: 22172255

Group type: EXPERIMENTAL
Intervention: Bacillus bifidus supplementation for 14 days after birth
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bacillus bifidus supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (conventional management only)
Number of subjects: 50
Study: 19586556

Group type: EXPERIMENTAL
Intervention: 9 microg CIFN
Number of subjects: 144

Group type: COMPARATOR
Intervention: 50 microg IFN-alpha1b
Number of subjects: 144
Study: 18000538

Group type: EXPERIMENTAL
Intervention: SP plus azithromycin (1 g/day x 2 days)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: SP plus artesunate (200 mg/day x 3 days)
Number of subjects: 141

Group type: COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP; 3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet)
Number of subjects: 141
Study: 15207199

Group type: EXPERIMENTAL
Intervention: Minimal intervention: mailing DI reports
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic intervention: DI report delivered in collective session managed by a trained doctor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized intervention: discussion peer-to-peer between FD and the trained doctor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: no DI information received
Number of subjects: 0
Study: 11448319

Group type: EXPERIMENTAL
Intervention: 125I brachytherapy
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 1317
Study: 9568678

Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with PSMA-derived peptides (PSM-P1 and PSM-P2)
Number of subjects: 0
Study: 8043996

Group type: EXPERIMENTAL
Intervention: Ligustrazine 160 mg intravenously for 10 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 59